HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Rare Cannabinoids, BioMedican Sees Alphabet Of Potential Dietary And Drug Ingredients

Executive Summary

BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.

You may also be interested in...



Expanding Crop Of Ingredients Could Shrink Support For Lawful Use Of Hemp In Supplements

Groups of House and Senate members who opposed legislation to de-schedule hemp as a controlled substance in 2018 remain opposed to also legalizing cannabis and could stifle support for making lawful hemp’s use in supplements.

BioMedican Pitches Cannabinoid Biosynthesis Investing; Cultivated Market Sprouts More Deals

BioMedican needs support until it can begin generating revenues and conduct an IPO. Businesses already marketing cannabinoid supplements receive more funding, or in some cases are acquired, as well as expand distribution.

FDA To Consider Regulatory Shift Making Cannabis Ingredients Officially Eligible For Use In Dietary Supplements

FDA's prohibition against using ingredients derived from the cannabis plant in supplements and food isn't lifted by the farm bill President Trump signed on Dec. 20, but the agency recognizes sales of supplement and food products containing cannabidiol and other cannabis derivatives are exploding in the US.

Topics

UsernamePublicRestriction

Register

RS151059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel